Drug Profile
Pentavalent meningococcal conjugate vaccine A C Y W 135 X - PATH/Serum Institute of India
Alternative Names: MenACYWX; MenFive; Meningococcal vaccine groups A,C,W-135, Y, X conjugate - PATH; Meningococcal-ACYWX-conjugate-vaccine; NmCV-5; Pentavalent-meningococcal-conjugate-vaccine-A-C-Y-W-135-X; Polyvalent meningitis vaccine - PATH; SIIPL Meningococcal ACYWX Conjugate Vaccine; Thermostable pentavalent conjugate meningococcal vaccine - PATHLatest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator PATH; Serum Institute of India
- Class Conjugate vaccines; Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Meningococcal infections
Most Recent Events
- 18 Sep 2023 Primordial Genetics has merged with Pelican Expression Technology to form Primrose Bio
- 12 Jul 2023 Pentavalent meningococcal conjugate vaccine A C Y W 135 X achieves World Health Organization (WHO) prequalification for Meningococcal infections (Prevention) in Africa
- 29 Oct 2021 Emory University and National Institute of Allergy and Infectious Diseases plans a phase III trial for Meningococcal infections (Prevention, In children, In infants) in Mali in February 2022 (NCT05093829)